July 19 (Reuters) - Valeant Pharmaceuticals InternationalInc's experimental drug to treat the skin disorderpsoriasis should be approved as long as certain measures are putin place to mitigate the risk of suicide, an advisory committeeto the U.S. Food and Drug Administration concluded on Tuesday.
The FDA is not obliged to follow the advice of its advisorycommittees but typically does so. (Reporting by Toni Clarke in Washington; Editing by AlanCrosby)